Cormedix Incis A Biopharmaceutical Company Based In Berkeley Heightsnew Jerseyfounded In 2006The Company Focuses On Developing And Commercializing Therapeutic Products For Life Threatening Diseasesparticularly Infections And Inflammatory Conditions One Of Its Key Products Is Defencatha An Antimicrobial Catheter Lock Solution Aimed At Reducing Catheter Related Bloodstream Infections In Adult Patients With Kidney Failure Undergoing Hemodialysisdefencathareceived Fda Approval In November 2023 And Is Set For Commercial Launch In Various Healthcare Settings In 2024Cormedix Is Also Working On Taurolidine Based Products For Medical Devices And Has Plans For Clinical Studies Targeting Pediatric Hemodialysis Patients And Adults Dependent On Total Parenteral Nutrition The Company Collaborates With Healthcare Providersincluding Nephrologists And Dialysis Centersto Address Catheter Related Infectionswith A Dedicated Team And A Focus On Expanding Its Product Offeringscormedix Is Committed To Advancing Healthcare Solutions
